Evidence map›Paper›PMID 33679731›Full record

ReviewFrontiers in immunology2021

Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.

Jérôme Granel, Brice Korkmaz, Dalila Nouar, Stefanie A I Weiss, Dieter E Jenne, Roxane Lemoine, Cyrille Hoarau

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Alpha-1 antitrypsin deficiency and granulomatosis with polyangiitis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  2. [From sudden hearing loss to an inflammatory systemic disease].Innere Medizin (Heidelberg, Germany) · 2026
    Article
  3. A Case Report of Granulomatosis with Polyangiitis Presenting with Chronic Conjunctivitis.Journal of education & teaching in emergency medicine · 2026
    Article
  4. Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  5. Potential impact of two functional variants in theCaspian journal of internal medicine · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Increased frequency of IgD-CD27Arthritis research & therapy · 2022
    Article
  20. Granulomatous Inflammation in ANCA-Associated Vasculitis.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Jérôme GranelUniversité de Tours, Plateforme B Cell Ressources (BCR) EA4245, Tours, France.
Brice KorkmazINSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.
Dalila NouarService d'Immunologie Clinique et d'Allergologie, Centre Hospitalier Régional Universitaire, Tours, France.
Stefanie A I WeissComprehensive Pneumology Center, Institute of Lung Biology and Disease, German Center for Lung Research (DZL) Munich and Max Planck Institute of Neurobiology, Planegg-Martinsried, Germany.
Dieter E JenneComprehensive Pneumology Center, Institute of Lung Biology and Disease, German Center for Lung Research (DZL) Munich and Max Planck Institute of Neurobiology, Planegg-Martinsried, Germany.
Roxane LemoineUniversité de Tours, Plateforme B Cell Ressources (BCR) EA4245, Tours, France.
Cyrille HoarauUniversité de Tours, Plateforme B Cell Ressources (BCR) EA4245, Tours, France.
Centre Hospitalier Universitaire de Tours · FRUniversité de Tours · FRGerman Center for Lung Research · DEInserm · FRMax Planck Institute of Neurobiology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Granulomatosis with polyangiitis (GPA) is a rare but serious necrotizing auto-immune vasculitis. GPA is mostly associated with the presence of Anti-Neutrophil Cytoplasmic Antibody (ANCA) targeting proteinase 3 (PR3-ANCA), a serine protease contained in neutrophil granules but also exposed at the membrane. PR3-ANCAs have a proven fundamental role in GPA: they bind neutrophils allowing their auto-immune activation responsible for vasculitis lesions. PR3-ANCAs bind neutrophil surface on the one hand by their Fab binding PR3 and on the other by their Fc binding Fc gamma receptors. Despite current therapies, GPA is still a serious disease with an important mortality and a high risk of relapse. Furthermore, although PR3-ANCAs are a consistent biomarker for GPA diagnosis, relapse management currently based on their level is inconsistent. Indeed, PR3-ANCA level is not correlated with disease activity in 25% of patients suggesting that not all PR3-ANCAs are pathogenic. Therefore, the development of new biomarkers to evaluate disease activity and predict relapse and new therapies is necessary. Understanding factors influencing PR3-ANCA pathogenicity,

Indexed as

Antibodies, Antineutrophil CytoplasmicBiomarkersGranulomatosis with PolyangiitisHumansMyeloblastinNeutrophilsPeroxidaseProtein BindingRecurrenceRisk FactorsAntibodies, Antineutrophil CytoplasmicBiomarkersMyeloblastinPeroxidaseanti-neutrophil cytoplasmic antibodiesbiomarkersgranulomatosis with polyangiitishuman neutrophilsnew therapiespathogenicityproteinase 3

Identifiers

PMID33679731
PMCPMC7930335
OpenAlexW3131643754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.